Dr. Reddy's Laboratories Limited(RDY)Earnings, Financials & Key Ratios
RDY•NYSE
$13.46
$11.21B mkt cap·18.9× P/E·Price updated May 6, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryLarge-scale generic drug manufacturers
AboutDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Show more
- Revenue$325.54B+16.6%
- EBITDA$88.9B+7.7%
- Net Income$56.54B+1.5%
- EPS (Diluted)67.77+1.5%
- Gross Margin58.5%-0.2%
- EBITDA Margin27.31%-7.7%
- Operating Margin22.07%-9.0%
- Net Margin17.37%-12.9%
- ROE18.31%-15.9%
- ROIC16.26%-14.8%
- Debt/Equity0.14+94.4%
- Interest Coverage25.40-35.8%
RDY Key Insights
Dr. Reddy's Laboratories Limited (RDY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 20.5%
- ✓Strong 5Y profit CAGR of 23.7%
- ✓Strong 5Y sales CAGR of 13.3%
- ✓Healthy 5Y average net margin of 15.1%
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RDY Price & Volume
Dr. Reddy's Laboratories Limited (RDY) stock price & volume — 10-year historical chart
Loading chart...
RDY Growth Metrics
Dr. Reddy's Laboratories Limited (RDY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.19%
5 Years13.27%
3 Years14.94%
TTM11.09%
Profit CAGR
10 Years9.81%
5 Years23.73%
3 Years33.87%
TTM5.42%
EPS CAGR
10 Years-6.29%
5 Years-10.41%
3 Years33.72%
TTM5.5%
Return on Capital
10 Years19.36%
5 Years24.4%
3 Years24.64%
Last Year21.97%
RDY Recent Earnings
Dr. Reddy's Laboratories Limited (RDY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (45%)●Beat Revenue 7/12 qtrs (70%)
Q1 2026Latest
Jan 21, 2026EPS
$0.16
Est $0.16
+0.0%
Revenue
$952M
Est $928M
+2.6%
Q1 2026
Jan 20, 2026EPS
$0.16
Est $0.16
+0.0%
Revenue
$952M
Est $928M
+2.6%
Q4 2025
Oct 24, 2025EPS
$0.19
Est $0.19
-1.4%
Revenue
$992M
Est $945M
+5.0%
Q3 2025
Jul 23, 2025EPS
$0.20
Est $0.21
-6.7%
Revenue
$997M
Est $1.0B
-2.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Jan 21, 2026 | $0.16vs $0.16+0.0% | $952Mvs $928M+2.6% |
| Q1 2026 | Jan 20, 2026 | $0.16vs $0.16+0.0% | $952Mvs $928M+2.6% |
| Q4 2025 | Oct 24, 2025 | $0.19vs $0.19-1.4% | $992Mvs $945M+5.0% |
| Q3 2025 | Jul 23, 2025 | $0.20vs $0.21-6.7% | $997Mvs $1.0B-2.2% |
Based on last 12 quarters of dataView full earnings history →
RDY Peer Comparison
Dr. Reddy's Laboratories Limited (RDY) competitors in Large-scale generic drug manufacturers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SUN | 9.13B | 66.91 | 18.28 | 11.05% | 1.57% | 7.27% | 2.01 | |
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 AMRX | 4.28B | 13.62 | 61.91 | 8.05% | 2.39% | 7.47% | 0.13 | |
 TEVA | 42.31B | 36.34 | 30.28 | 4.31% | 9.02% | 20.69% | 2.20 | |
 VTRS | 18.37B | 15.95 | -5.32 | -2.98% | -24.58% | -23.89% | 0.98 | |
 MCK | 91.09B | 743.67 | 28.91 | 16.22% | 1.09% | |||
 CAH | 45.06B | 191.49 | 29.69 | -1.87% | 0.62% | |||
 CVS | 111.32B | 86.86 | 62.49 | 7.85% | 0.72% | 3.86% | 1.24 |
Compare RDY vs Peers
Dr. Reddy's Laboratories Limited (RDY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RDY Income Statement
Dr. Reddy's Laboratories Limited (RDY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 140.81B | 142.03B | 153.85B | 174.6B | 2.56B | 214.39B | 245.88B | 279.16B | 325.54B | 345.83B |
| Revenue Growth % | -8.98% | 0.87% | 8.32% | 13.49% | -98.54% | 8288.76% | 14.69% | 13.54% | 16.61% | 11.09% |
| Cost of Goods Sold | 62.45B | 65.72B | 70.42B | 80.59B | 1.26B | 100.55B | 106.54B | 115.56B | 135.11B | 155B |
| COGS % of Revenue | 44.35% | 46.28% | 45.77% | 46.16% | 49.22% | 46.9% | 43.33% | 41.39% | 41.5% | - |
| Gross Profit | 78.36B▲ 0% | 76.3B▼ 2.6% | 83.43B▲ 9.3% | 94.01B▲ 12.7% | 1.3B▼ 98.6% | 113.84B▲ 8671.8% | 139.34B▲ 22.4% | 163.61B▲ 17.4% | 190.43B▲ 16.4% | 190.84B▲ 0% |
| Gross Margin % | 55.65% | 53.72% | 54.23% | 53.84% | 50.78% | 53.1% | 56.67% | 58.61% | 58.5% | 55.18% |
| Gross Profit Growth % | -15.09% | -2.62% | 9.34% | 12.68% | -98.62% | 8671.79% | 22.4% | 17.41% | 16.39% | - |
| Operating Expenses | 64.86B | 64.39B | 62.54B | 78.02B | 866.36M | 84.36B | 82.2B | 95.88B | 118.58B | 123.96B |
| OpEx % of Revenue | 46.06% | 45.33% | 40.65% | 44.68% | 33.9% | 39.35% | 33.43% | 34.34% | 36.43% | - |
| Selling, General & Admin | 46.37B | 46.91B | 48.89B | 0 | 659.9M | 62.08B | 68.03B | 77.2B | 93.87B | 100.59B |
| SG&A % of Revenue | 32.93% | 33.03% | 31.78% | - | 25.82% | 28.96% | 27.67% | 27.65% | 28.84% | - |
| Research & Development | 19.55B | 18.27B | 15.61B | 15.41B | 208.37M | 17.48B | 19.38B | 22.87B | 27.38B | 25.85B |
| R&D % of Revenue | 13.88% | 12.86% | 10.14% | 8.83% | 8.15% | 8.15% | 7.88% | 8.19% | 8.41% | - |
| Other Operating Expenses | -1.15B | -843M | -691M | 62.61B | 1.91M | 4.8B | -5.21B | -4.2B | -2.67B | -2M |
| Operating Income | 13.5B▲ 0% | 11.92B▼ 11.7% | 20.89B▲ 75.3% | 15.99B▼ 23.4% | 431.44M▼ 97.3% | 29.48B▲ 6732.0% | 57.14B▲ 93.9% | 67.73B▲ 18.5% | 71.84B▲ 6.1% | 66.87B▲ 0% |
| Operating Margin % | 9.59% | 8.39% | 13.58% | 9.16% | 16.88% | 13.75% | 23.24% | 24.26% | 22.07% | 19.34% |
| Operating Income Growth % | -54.43% | -11.71% | 75.28% | -23.43% | -97.3% | 6732% | 93.87% | 18.52% | 6.07% | - |
| EBITDA | 24.77B | 23.63B | 33.08B | 28.46B | 603.81M | 41.3B | 69.78B | 82.57B | 88.9B | 86.29B |
| EBITDA Margin % | 17.59% | 16.64% | 21.5% | 16.3% | 23.63% | 19.26% | 28.38% | 29.58% | 27.31% | 24.95% |
| EBITDA Growth % | -37.86% | -4.63% | 40% | -13.95% | -97.88% | 6739.88% | 68.96% | 18.33% | 7.67% | 1.08% |
| D&A (Non-Cash Add-back) | 11.28B | 11.71B | 12.19B | 12.47B | 172.37M | 11.82B | 12.64B | 14.84B | 17.06B | 19.42B |
| EBIT | 15.29B | 15.13B | 23.33B | 29.31B | 362.4M | 33.26B | 61.8B | 73.58B | 79.61B | 74.35B |
| Net Interest Income | -76M | -248M | -119M | -1.27M | -144M | 7M | -248M | 567M | -152M | 2.16B |
| Interest Income | 558M | 540M | 770M | 12.59M | 826M | 965M | 1.18B | 2.28B | 2.68B | 5.5B |
| Interest Expense | 634M | 788M | 889M | 13.86M | 970M | 958M | 1.43B | 1.71B | 2.83B | 3.34B |
| Other Income/Expense | 1.16B | 2.42B | 1.55B | 2.04B | -75.64M | 2.82B | 3.22B | 4.14B | 4.94B | 6.01B |
| Pretax Income | 14.65B▲ 0% | 14.34B▼ 2.1% | 22.44B▲ 56.5% | 18.03B▼ 19.7% | 355.8M▼ 98.0% | 32.3B▲ 8977.5% | 60.37B▲ 86.9% | 71.87B▲ 19.1% | 76.78B▲ 6.8% | 72.88B▲ 0% |
| Pretax Margin % | 10.41% | 10.1% | 14.59% | 10.33% | 13.92% | 15.07% | 24.55% | 25.74% | 23.59% | 21.07% |
| Income Tax | 2.61B | 4.54B | 3.65B | -1.47B | 123.59M | 8.73B | 15.3B | 16.19B | 19.54B | 16.75B |
| Effective Tax Rate % | 17.84% | 31.62% | 16.25% | -8.13% | 34.74% | 27.03% | 25.34% | 22.52% | 25.45% | 22.98% |
| Net Income | 12.04B▲ 0% | 9.81B▼ 18.5% | 18.8B▲ 91.7% | 19.5B▲ 3.7% | 232.21M▼ 98.8% | 23.57B▲ 10049.5% | 45.07B▲ 91.2% | 55.68B▲ 23.6% | 56.54B▲ 1.5% | 56.59B▲ 0% |
| Net Margin % | 8.55% | 6.9% | 12.22% | 11.17% | 9.09% | 10.99% | 18.33% | 19.95% | 17.37% | 16.36% |
| Net Income Growth % | -39.84% | -18.55% | 91.67% | 3.74% | -98.81% | 10049.5% | 91.22% | 23.56% | 1.54% | 5.42% |
| Net Income (Continuing) | 12.04B | 9.81B | 18.8B | 19.5B | 232.21M | 23.57B | 45.07B | 55.68B | 57.24B | 56.13B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.78B | 3.39B |
| EPS (Diluted) | 72.09▲ 0% | 59.01▼ 18.1% | 113.09▲ 91.6% | 117.40▲ 3.8% | 20.73▼ 82.3% | 28.34▲ 36.7% | 54.17▲ 91.1% | 66.80▲ 23.3% | 67.77▲ 1.5% | 67.91▲ 0% |
| EPS Growth % | -38.37% | -18.14% | 91.65% | 3.81% | -82.34% | 36.71% | 91.14% | 23.32% | 1.45% | 5.5% |
| EPS (Basic) | 72.24 | 59.13 | 113.28 | 117.63 | 20.79 | 28.42 | 54.29 | 66.80 | 67.85 | - |
| Diluted Shares Outstanding | 834.99M | 830.93M | 830.98M | 830.41M | 831.58M | 831.69M | 831.91M | 833.54M | 834.3M | 833.2M |
| Basic Shares Outstanding | 833.24M | 829.19M | 829.58M | 828.79M | 829.22M | 829.41M | 830.17M | 833.54M | 833.31M | 833.2M |
| Dividend Payout Ratio | 28.16% | 40.71% | 21.29% | 20.08% | 1785.9% | 17.59% | 11.05% | 11.94% | 11.78% | - |
RDY Balance Sheet
Dr. Reddy's Laboratories Limited (RDY) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 100.38B | 109.64B | 114.5B | 1.72B | 2.03B | 181.86B | 204.25B | 248.05B | 250.11B | 297.55B |
| Cash & Short-Term Investments | 18.14B | 20.97B | 24.76B | 340.25M | 472.87M | 44.37B | 61.8B | 81.47B | 57.91B | 82.59B |
| Cash Only | 18.14B | 2.64B | 2.23B | 27.14M | 202.82M | 14.85B | 5.78B | 7.11B | 14.65B | 18.66B |
| Short-Term Investments | 0 | 18.33B | 22.53B | 313.11M | 270.04M | 29.51B | 56.02B | 74.36B | 43.25B | 63.93B |
| Accounts Receivable | 45.74B | 50.2B | 46.63B | 816.3M | 843.66M | 80.27B | 83.2B | 95.34B | 109.79B | 124.27B |
| Days Sales Outstanding | 118.56 | 129.01 | 110.63 | 1.71 | 120.49 | 136.66 | 123.51 | 124.65 | 123.1 | 124.1 |
| Inventory | 28.53B | 29.09B | 33.58B | 463.52M | 621.11M | 50.88B | 48.67B | 63.55B | 71.08B | 79.01B |
| Days Inventory Outstanding | 166.73 | 161.55 | 174.04 | 2.1 | 180.23 | 184.71 | 166.75 | 200.74 | 192.04 | 177.51 |
| Other Current Assets | 14.93B | 18.21B | 15.35B | 90.68M | 74.4M | 5.2B | 6.41B | 2.94B | 4.56B | 5.51B |
| Total Non-Current Assets | 119.45B | 115.96B | 110.93B | 1.35B | 1.6B | 110.97B | 117.6B | 139.47B | 242.88B | 265.35B |
| Property, Plant & Equipment | 57.16B | 57.87B | 54.09B | 691.75M | 781.13M | 62.17B | 66.46B | 76.89B | 97.76B | 115.54B |
| Fixed Asset Turnover | 2.46x | 2.45x | 2.84x | 252.40x | 3.27x | 3.45x | 3.70x | 3.63x | 3.33x | 3.23x |
| Goodwill | 3.75B | 3.94B | 3.9B | 52.79M | 62.48M | 4.42B | 4.25B | 4.25B | 11.81B | 12.41B |
| Intangible Assets | 44.92B | 44.66B | 44.37B | 365.61M | 487.57M | 27.25B | 30.85B | 36.95B | 96.8B | 102.32B |
| Long-Term Investments | 6.84B | 4.65B | 3.34B | 63.82M | 115.59M | 7.99B | 5.36B | 5.25B | 15.2B | 46.34B |
| Other Non-Current Assets | 1.19B | 1.2B | 1.06B | 11.16M | 11.41M | 948M | 3.49B | 5.35B | 2.79B | 15.13B |
| Total Assets | 219.82B▲ 0% | 225.6B▲ 2.6% | 225.43B▼ 0.1% | 3.07B▼ 98.6% | 3.63B▲ 18.3% | 292.83B▲ 7964.2% | 321.85B▲ 9.9% | 387.52B▲ 20.4% | 492.99B▲ 27.2% | 562.9B▲ 0% |
| Asset Turnover | 0.64x | 0.63x | 0.68x | 56.88x | 0.70x | 0.73x | 0.76x | 0.72x | 0.66x | 0.65x |
| Asset Growth % | 5.86% | 2.63% | -0.08% | -98.64% | 18.28% | 7964.18% | 9.91% | 20.4% | 27.22% | 85.65% |
| Total Current Liabilities | 85B | 69.69B | 59.7B | 962.5M | 1.14B | 94.02B | 85.84B | 96.04B | 130.39B | 158.31B |
| Accounts Payable | 0 | 9.21B | 10.3B | 142.03M | 173.65M | 15.97B | 17.86B | 21.55B | 20.05B | 40.8B |
| Days Payables Outstanding | - | 51.14 | 53.37 | 0.64 | 50.39 | 57.97 | 61.18 | 68.06 | 54.17 | 81.57 |
| Short-Term Debt | 43.74B | 25.56B | 16.32B | 274.92M | 328.38M | 27.08B | 11.19B | 12.72B | 38.05B | 54.09B |
| Deferred Revenue (Current) | 819M | 982M | 1.35B | 25.25M | 27.81M | 2.58B | 1.98B | 1.44B | 1.98B | 7.66B |
| Other Current Liabilities | 8.91B | 11.04B | 9.21B | 447.37M | 515.05M | 6.76B | 9.19B | 11.42B | 13.52B | 15.85B |
| Current Ratio | 1.18x | 1.57x | 1.92x | 1.79x | 1.78x | 1.93x | 2.38x | 2.58x | 1.92x | 1.92x |
| Quick Ratio | 0.85x | 1.16x | 1.36x | 1.31x | 1.23x | 1.39x | 1.81x | 1.92x | 1.37x | 1.37x |
| Cash Conversion Cycle | - | 239.42 | 231.3 | 3.16 | 250.33 | 263.39 | 229.08 | 257.33 | 260.97 | 220.04 |
| Total Non-Current Liabilities | 10.78B | 29.45B | 25.53B | 58.68M | 123.62M | 8.29B | 5.02B | 10.93B | 25.43B | 28.83B |
| Long-Term Debt | 4.85B | 24.46B | 21.45B | 0 | 51.97M | 3.8B | 0 | 3.8B | 3.8B | 0 |
| Capital Lease Obligations | 597M | 630M | 552M | 17.24M | 34.18M | 1.95B | 1.28B | 2.19B | 4.06B | 32.41B |
| Deferred Tax Liabilities | 1.2B | 730M | 610M | 3.64M | 4.62M | 60M | 833M | 909M | 14.11B | 58.16B |
| Other Non-Current Liabilities | 5.33B | 4.36B | 918M | 11.95M | 11.9M | 882M | 1.35B | 2.84B | 2.3B | 6.76B |
| Total Liabilities | 95.78B | 99.14B | 85.23B | 1.02B | 1.26B | 102.3B | 90.86B | 106.97B | 155.82B | 187.14B |
| Total Debt | 49.19B | 50.71B | 38.38B | 292.16M | 414.53M | 33.84B | 13.47B | 20.02B | 46.77B | 67.73B |
| Net Debt | 31.05B | 48.08B | 36.15B | 265.02M | 211.71M | 18.99B | 7.69B | 12.91B | 32.11B | 49.08B |
| Debt / Equity | 0.40x | 0.40x | 0.27x | 0.14x | 0.18x | 0.18x | 0.06x | 0.07x | 0.14x | 0.14x |
| Debt / EBITDA | 1.99x | 2.15x | 1.16x | 0.01x | 0.69x | 0.82x | 0.19x | 0.24x | 0.53x | 0.78x |
| Net Debt / EBITDA | 1.25x | 2.03x | 1.09x | 0.01x | 0.35x | 0.46x | 0.11x | 0.16x | 0.36x | 0.36x |
| Interest Coverage | 21.29x | 15.12x | 23.50x | 1153.61x | 0.44x | 30.77x | 40.02x | 39.58x | 25.40x | 22.23x |
| Total Equity | 124.04B▲ 0% | 126.46B▲ 1.9% | 140.2B▲ 10.9% | 2.05B▼ 98.5% | 2.37B▲ 15.5% | 190.53B▲ 7949.2% | 230.99B▲ 21.2% | 280.55B▲ 21.5% | 337.17B▲ 20.2% | 375.76B▲ 0% |
| Equity Growth % | -3.34% | 1.95% | 10.86% | -98.54% | 15.54% | 7949.22% | 21.24% | 21.45% | 20.18% | 74.17% |
| Book Value per Share | 148.56 | 152.19 | 168.71 | 2.47 | 2.85 | 229.08 | 277.66 | 336.58 | 404.13 | 450.98 |
| Total Shareholders' Equity | 124.04B | 126.46B | 140.2B | 2.05B | 2.37B | 190.53B | 230.99B | 280.55B | 333.39B | 372.37B |
| Common Stock | 829M | 830M | 830M | 10.98M | 11.38M | 832M | 833M | 834M | 834M | 835M |
| Retained Earnings | 108.22B | 113.86B | 128.65B | 1.91B | 2.13B | 175.71B | 215.59B | 265.26B | 315.79B | 349.78B |
| Treasury Stock | 0 | 0 | -535M | -13.3M | -26.9M | -1.6B | -1.27B | -991M | -2.26B | -1.9B |
| Accumulated OCI | 7.8B | 3.98B | 3.04B | 32M | 127.02M | 755M | 886M | 653M | 3.98B | 3.98B |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.78B | 3.39B |
RDY Cash Flow Statement
Dr. Reddy's Laboratories Limited (RDY) cash flow — operating, investing & free cash flow history
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 21.51B | 18.03B | 28.7B | 29.84B | 35.7B | 28.11B | 58.88B | 45.43B | 46.43B | 46.43B |
| Operating CF Margin % | 15.28% | 12.69% | 18.66% | 17.09% | 1397% | 13.11% | 23.94% | 16.27% | 14.26% | - |
| Operating CF Growth % | -47.84% | -16.19% | 59.21% | 3.96% | 19.64% | -21.27% | 109.46% | -22.83% | 2.19% | 16254.85% |
| Net Income | 12.04B | 9.81B | 18.8B | 19.5B | 17.24B | 23.57B | 45.07B | 55.68B | 57.24B | 56.59B |
| Depreciation & Amortization | 11.28B | 11.71B | 12.19B | 12.47B | 12.8B | 11.82B | 12.64B | 14.84B | 17.06B | 19.58B |
| Stock-Based Compensation | 398M | 454M | 389M | 521M | 584M | 592M | 397M | 407M | 424M | 345M |
| Deferred Taxes | 2.61B | 4.54B | 3.65B | -1.47B | 9.18B | 8.73B | 15.3B | 16.19B | 19.54B | 16.75B |
| Other Non-Cash Items | 535M | 488M | -547M | 6.35B | 6.63B | -2.69B | -6.67B | -21.5B | -17.85B | -11.41B |
| Working Capital Changes | -5.35B | -8.96B | -5.77B | -7.54B | -10.72B | -13.91B | -7.86B | -20.18B | -29.99B | -18.29B |
| Change in Receivables | 3.04B | -2.1B | 1.8B | -12.45B | 2.08B | -17.01B | -5.75B | -8.05B | -10.28B | -8.28B |
| Change in Inventory | -6.33B | -3.23B | -8.5B | -1.49B | -12.4B | -5.33B | -2.65B | -18.45B | -12.75B | -10.71B |
| Change in Payables | 0 | 0 | -1.8B | 0 | 0 | 17.01B | 0 | 0 | 0 | 0 |
| Cash from Investing | -18.47B | -14.88B | -7.73B | -4.92B | -22.66B | -26.39B | -41.37B | -40.28B | -58.08B | -52.33B |
| Capital Expenditures | -40.98B | -11.04B | -7.49B | -4.85B | -9.74B | -19.05B | -11.32B | -16.4B | -27.5B | -26.45B |
| CapEx % of Revenue | 29.11% | 7.78% | 4.87% | 2.78% | 381.15% | 8.89% | 4.61% | 5.88% | 8.45% | - |
| Acquisitions | -103M | 1.75B | 536M | 0 | -15.51B | -326M | 0 | -12M | -53.41B | -1.71B |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 672M | -1.2B | 1.51B | 137M | -1.51B | 4.19B | -6.68B | -8.16B | -2.28B | -9.38B |
| Cash from Financing | -3.69B | -4.44B | -21.33B | -25.16B | -298M | -2.42B | -26.86B | -3.76B | 18.91B | -6.12B |
| Debt Issued (Net) | -5.22B | 882M | -15.18B | -19.16B | 6.09B | 2.73B | -20.4B | 4.35B | 23.2B | 5.65B |
| Equity Issued (Net) | -1000K | 1000K | -1000K | -1000K | -1000K | 1000K | 1000K | 1000K | -1000K | 2M |
| Dividends Paid | -3.39B | -3.99B | -4B | -3.92B | -4.15B | -4.15B | -4.98B | -6.65B | -6.66B | -6.66B |
| Share Repurchases | -15.69B | 0 | -535M | -474M | -1.19B | 0 | 0 | 0 | -1.39B | -1.39B |
| Other Financing | 20.61B | -1.33B | -1.61B | -1.61B | -1.32B | -1.34B | -1.85B | -2.27B | 3.57B | 3.01B |
| Net Change in Cash | -1.14B▲ 0% | -1.24B▼ 8.3% | -314M▲ 74.6% | -266M▲ 15.3% | 12.86B▲ 4933.8% | 32M▼ 99.8% | -9.07B▼ 28453.1% | 1.33B▲ 114.6% | 7.49B▲ 463.7% | 5.63B▲ 0% |
| Free Cash Flow | -19.47B▲ 0% | 6.99B▲ 135.9% | 21.21B▲ 203.7% | 23.73B▲ 11.8% | 23.14B▼ 2.5% | 9.06B▼ 60.9% | 40.01B▲ 341.6% | 18B▼ 55.0% | 12.03B▼ 33.2% | 24.26B▲ 0% |
| FCF Margin % | -13.83% | 4.92% | 13.79% | 13.59% | 905.51% | 4.23% | 16.27% | 6.45% | 3.7% | 7.01% |
| FCF Growth % | -173.83% | 135.88% | 203.65% | 11.85% | -2.46% | -60.85% | 341.65% | -55.02% | -33.16% | 1693.03% |
| FCF per Share | -23.32 | 8.41 | 25.53 | 28.57 | 27.83 | 10.89 | 48.09 | 21.59 | 14.42 | 14.42 |
| FCF Conversion (FCF/Net Income) | 1.79x | 1.84x | 1.53x | 1.53x | 153.75x | 1.19x | 1.31x | 0.82x | 0.82x | 0.43x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RDY Key Ratios
Dr. Reddy's Laboratories Limited (RDY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 9.54% | 7.83% | 14.1% | 27.41% | 10.52% | 24.44% | 21.38% | 21.77% | 18.31% | 15.06% |
| Return on Invested Capital (ROIC) | 7.31% | 5.42% | 8.93% | 13.43% | 13.23% | 20.85% | 19.12% | 19.09% | 16.26% | 16.26% |
| Gross Margin | 55.65% | 53.72% | 54.23% | 53.84% | 50.78% | 53.1% | 56.67% | 58.61% | 58.5% | 55.18% |
| Net Margin | 8.55% | 6.9% | 12.22% | 11.17% | 9.09% | 10.99% | 18.33% | 19.95% | 17.37% | 16.36% |
| Debt / Equity | 0.40x | 0.40x | 0.27x | 0.14x | 0.18x | 0.18x | 0.06x | 0.07x | 0.14x | 0.14x |
| Interest Coverage | 21.29x | 15.12x | 23.50x | 1153.61x | 0.44x | 30.77x | 40.02x | 39.58x | 25.40x | 22.23x |
| FCF Conversion | 1.79x | 1.84x | 1.53x | 1.53x | 153.75x | 1.19x | 1.31x | 0.82x | 0.82x | 0.43x |
| Revenue Growth | -8.98% | 0.87% | 8.32% | 13.49% | -98.54% | 8288.76% | 14.69% | 13.54% | 16.61% | 11.09% |
RDY Frequently Asked Questions
Dr. Reddy's Laboratories Limited (RDY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Dr. Reddy's Laboratories Limited (RDY) reported $345.83B in revenue for fiscal year 2025. This represents a 3063% increase from $10.94B in 2001.
Dr. Reddy's Laboratories Limited (RDY) grew revenue by 16.6% over the past year. This is strong growth.
Yes, Dr. Reddy's Laboratories Limited (RDY) is profitable, generating $56.59B in net income for fiscal year 2025 (17.4% net margin).
Dividend & Returns
Yes, Dr. Reddy's Laboratories Limited (RDY) pays a dividend with a yield of 0.62%. This makes it attractive for income-focused investors.
Dr. Reddy's Laboratories Limited (RDY) has a return on equity (ROE) of 18.3%. This is reasonable for most industries.
Dr. Reddy's Laboratories Limited (RDY) generated $24.26B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More RDY
Dr. Reddy's Laboratories Limited (RDY) financial analysis — history, returns, DCA and operating performance tools
Full RDY Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates